CORE-017: CLINICAL PROTOCOL AND DATA MANAGEMENT (CPDM) PROJECT SUMMARY / ABSTRACT The Clinical Protocol and Data Management (CPDM) function of the OSUCCC provides comprehensive resources for the conduct of cancer clinical research with an emphasis on the inclusion of women, minorities, children and other underserved populations. The CPDM is overseen by Dr. William Carson, the Associate Director for Clinical Research (ADCR). The cancer center's Clinical Trials Office (CTO), supports the centralized administration of protocol development, implementation and conduct for all clinically active cancer research groups. No clinical cancer research may be conducted outside the CTO. Thus, the CTO oversees all cancer clinical trials and is the centralized organization for the conduct of such research. This team provides the trial administration, protocol tracking and monitoring, data management, regulatory processing and financial supervision necessary for the successful conduct of clinical trials in a methodologically-sound, expedient, and cost-effective manner. The CTO Medical Director is Steven Devine, MD and the CTO Medical Co-Director is Dr. Bhuvana Ramaswamy, MD. The CTO interim Administrative Director is Nancy Single, PhD. The OSUCCC Data and Safety Monitoring Plan outlines the structure and responsibilities of the Data and Safety Monitoring Committee (DSMC) which oversees and reviews the safe conduct of clinical research at this cancer center. The DSMC is headed by William Blum, MD. The inclusion of women, minorities and children in cancer clinical research is an important goal of this organization and effort in this area are coordinated by the Center for Cancer Health Equity under the leadership of Electra Paskett, PhD, OSUCCC Associate Director for Population Sciences.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016058-44
Application #
9843878
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2019-12-01
Budget End
2020-11-30
Support Year
44
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Ohio State University
Department
Type
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
O'Brien, Susan M; Jaglowski, Samantha; Byrd, John C et al. (2018) Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of 2 Clinical Trials. JAMA Oncol 4:712-716
Guo, Sijin; Piao, Xijun; Li, Hui et al. (2018) Methods for construction and characterization of simple or special multifunctional RNA nanoparticles based on the 3WJ of phi29 DNA packaging motor. Methods 143:121-133
Sadowski, Abbey R; Gardner, Heather L; Borgatti, Antonella et al. (2018) Phase II study of the oral selective inhibitor of nuclear export (SINE) KPT-335 (verdinexor) in dogs with lymphoma. BMC Vet Res 14:250
Barredo, Julio C; Hastings, Caroline; Lu, Xiamin et al. (2018) Isolated late testicular relapse of B-cell acute lymphoblastic leukemia treated with intensive systemic chemotherapy and response-based testicular radiation: A Children's Oncology Group study. Pediatr Blood Cancer 65:e26928
Kim, So-Youn; Nair, Devi M; Romero, Megan et al. (2018) Transient inhibition of p53 homologs protects ovarian function from two distinct apoptotic pathways triggered by anticancer therapies. Cell Death Differ :
Yadav, Marshleen; Song, Feifei; Huang, Jason et al. (2018) Ocimum flavone Orientin as a countermeasure for thrombocytopenia. Sci Rep 8:5075
Siegel, Marni B; He, Xiaping; Hoadley, Katherine A et al. (2018) Integrated RNA and DNA sequencing reveals early drivers of metastatic breast cancer. J Clin Invest 128:1371-1383
White, Brian S; Lanc, Irena; O'Neal, Julie et al. (2018) A multiple myeloma-specific capture sequencing platform discovers novel translocations and frequent, risk-associated point mutations in IGLL5. Blood Cancer J 8:35
Owen, Dwight; Chaft, Jamie E (2018) Immunotherapy in surgically resectable non-small cell lung cancer. J Thorac Dis 10:S404-S411
Barajas, Juan M; Reyes, Ryan; Guerrero, Maria J et al. (2018) The role of miR-122 in the dysregulation of glucose-6-phosphate dehydrogenase (G6PD) expression in hepatocellular cancer. Sci Rep 8:9105

Showing the most recent 10 out of 2602 publications